N-methyl-2-pyridone-5-carboxamide: A novel uremic toxin? Boleslaw Rutkowski, Ewa Slominska, Marek Szolkiewicz, Ryszard T. Smolenski, Cindy Striley, Przemyslaw Rutkowski, Julian Swierczynski  Kidney International  Volume 63, Pages S19-S21 (May 2003) DOI: 10.1046/j.1523-1755.63.s84.36.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 The pathway of nicotinamide-adenine dinucleotide (NAD) degradation. Kidney International 2003 63, S19-S21DOI: (10.1046/j.1523-1755.63.s84.36.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 2 The serum 2PY concentration in patients with different severities of renal insufficiency. The effect of hemodialysis (4 hour sessions; polysulphone membrane) and kidney transplantation. Control, control group (N = 19); CRF, groups (N = 10) of nondialyzed patients with CRF and serum creatinine concentration; CRF1, 210.3 ± 98.5; CRF2, 540.1 ± 68.2; CRF3, 827.6 ± 145.7; HD, group (N = 11) of patients on hemodialysis treatment with serum creatinine concentration; HD1 (before HD), 733.6 ± 128.8; HD2 (after HD), 324.2 ± 73.4; HD3 (48 hours after HD), 707 ± 112.1; TN, group (N = 12) of patients after kidney transplantation with serum creatinine concentration: 111.3 ± 20.1. Serum creatinine concentration expressed in μmol/L. Statistical analysis shows CRF1 vs. control; P < 0.001; CRF2 vs. CRF1; P < 0.005; CRF3 vs. CRF2; P < 0.05; HD1 vs. CRF3; NS; HD2 vs. HD1, and HD3 vs. HD2; P < 0.001; TN vs. control; P < 0.01. Kidney International 2003 63, S19-S21DOI: (10.1046/j.1523-1755.63.s84.36.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 3 The effect of increasing concentrations of nicotinamide and 2PY on the purified PARP-1 activity. Nicotinamide is designated with a □, and 2PY is designated with a ▪. Kidney International 2003 63, S19-S21DOI: (10.1046/j.1523-1755.63.s84.36.x) Copyright © 2003 International Society of Nephrology Terms and Conditions